Christof Vulsteke discusses KEYNOTE-905 results with Ashish Kamat. The phase 3 trial enrolled cisplatin-ineligible muscle-invasive bladder cancer patients, median age 73, receiving perioperative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback